La Da

La Da

Auto-generated profile, based on publicly available information

La Da

Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
YQYunkai Qie
Yunkai Qie
SHShiwang Huang
Shiwang Huang
CSChong Shen
Chong Shen
ZWZhouliang Wu
Zhouliang Wu
LDLa Da
La Da
HHHailong Hu
Hailong Hu
Purpose: Combinations of immune checkpoint inhibitors and nab-paclitaxel have improved outcomes in advanced urothelial carcinoma and muscle-invasive bladder cancer. This study evaluates the safety and efficacy of tislelizumab combined with low-dose nab-paclitaxel in extensive very high–risk non–muscle-invasive bladder cancer. Patients and Methods: TRUCE-02 was a single-arm phase II trial that included 63 patients with visually incomplete resection and/or high-volume high-grade T1 tumors (with or without carcinoma in situ) who were ineligible for or declined radical cystectomy. Patients received intravenous tislelizumab (200 mg on day 1) and nab-paclitaxel (200 mg on day 2) every 3 weeks, with assessment approximately 3 months after initial administration. The primary endpoint was the complete response (CR) rate of high-risk disease. Main secondary endpoints included safety and duration of CR. Results: The safety analysis included all 63 patients, and the efficacy analysis included 59 patients. Thirty-seven patients (62.7%; 95% confidence interval, 49.1%–75.0%) achieved a CR of high-risk disease, with a 24-month sustained response rate of 96.3% (95% confidence interval, 89.4%–100.0%). Grade 3 to 4 treatment-related adverse events occurred in nine patients (14%), with no fatal events reported. Conclusions: Tislelizumab plus low-dose nab-paclitaxel was well tolerated and showed promising antitumor activity, making it a potential alternative for patients with extensive very high–risk non–muscle-invasive bladder cancer who are ineligible for or decline radical cystectomy.

3 March 2025
Verified
Other
Open access
PDF file
YQYunkai Qie
Yunkai Qie
SHShiwang Huang
Shiwang Huang
CSChong Shen
Chong Shen
ZWZhouliang Wu
Zhouliang Wu
LDLa Da
La Da
HHHailong Hu
Hailong Hu
Supplementary Table S4. Summary of all subsequent treatments.

3 March 2025
Verified
Other
Open access
YQYunkai Qie
Yunkai Qie
SHShiwang Huang
Shiwang Huang
CSChong Shen
Chong Shen
ZWZhouliang Wu
Zhouliang Wu
LDLa Da
La Da
HHHailong Hu
Hailong Hu
Supplementary Table S1. Representativeness of Study Participants.

3 March 2025
Verified
Other
Open access
PDF file
YQYunkai Qie
Yunkai Qie
SHShiwang Huang
Shiwang Huang
CSChong Shen
Chong Shen
ZWZhouliang Wu
Zhouliang Wu
LDLa Da
La Da
HHHailong Hu
Hailong Hu
Supplementary Figure S2. Duration of complete response of any disease.

3 March 2025
Verified
Other
Open access
PDF file
YQYunkai Qie
Yunkai Qie
SHShiwang Huang
Shiwang Huang
CSChong Shen
Chong Shen
ZWZhouliang Wu
Zhouliang Wu
LDLa Da
La Da
HHHailong Hu
Hailong Hu
Supplementary Table S3. Immune-mediated adverse events.